Pharmacy Medical News about efavirenz; HIV infection; neuropsychiatric adverse events

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Stepped-Dose Versus Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events
Annals of Internal Medicine, 08/13/09

Gutierrez–Valencia A et al. – Efavirenz is a powerful component of effective highly active antiretroviral therapy. Unfortunately, about half of patients develop disturbing neuropsychiatric side effects. Although side effects subside for many patients as they continue to take the drug, other patients have to stop taking efavirenz. This randomized trial compared full–dose efavirenz with stepped–dose efavirenz during the first 2 weeks of treatment and found fewer side effects during the first week in patients receiving stepped–dose therapy. After 24 weeks, HIV RNA levels and CD4+ cell counts were similar in both groups.

<< Previous
Multaq (dronedarone) for Atrial Fibrillation Now Approved in...

Next >>
Once-Daily Atomoxetine for Treating Pediatric...